Establishment Labs saw a 45.2% revenue increase in Q4 2025, driven by strong demand for Motiva and the launch of Preservé. The company achieved a milestone of positive adjusted EBITDA for the second half of the year and significantly narrowed its operating loss.

Establishment Labs delivered a robust third quarter in 2025, with worldwide revenue reaching $53.8 million, a 33.8% increase year-over-year. The company achieved a significant milestone by reporting positive Adjusted EBITDA of $1.2 million, ahead of the fourth quarter, and improved its gross margin to 70.1%. Net loss also narrowed to $11.1 million from $16.7 million in the prior year.

Establishment Labs reported a strong second quarter in 2025, with worldwide revenue increasing by 16.3% year-over-year to $51.3 million, driven by significant Motiva sales in the United States. The company also improved its gross margin to 68.8% and reduced its adjusted EBITDA loss and cash use compared to the previous quarter, indicating increasing scale and improved cost efficiencies. The company raised its full-year revenue guidance.

Establishment Labs reported a 11.3% increase in revenue to $41.4 million in Q1 2025 compared to the prior year, primarily driven by strong U.S. sales. Despite the revenue growth, the company experienced increased operating expenses, resulting in a higher net loss and adjusted EBITDA loss compared to Q1 2024. The cash balance at the end of the quarter was $69.2 million.

Establishment Labs reported a fourth quarter revenue of $44.5 million, consistent with preannouncement, and a net loss from operations of $18.7 million, which was a 15% reduction compared to the prior year. The company also saw its adjusted EBITDA loss improve by 25% to $13.1 million.

Establishment Labs reported third quarter revenue of $40.2 million. The company updated its 2024 revenue guidance to $165 million to $168 million. The U.S. launch of Motiva has exceeded expectations, with over 250 new accounts onboarded in the first three weeks. The company's cash balance as of September 30, 2024, was $39.7 million, with a pro forma cash balance of approximately $114.0 million including recent financing activities.

Establishment Labs reported a decrease in revenue for the second quarter of 2024, with $44.1 million compared to $48.6 million in the same period of 2023. However, the company saw an improvement in gross profit margin and a reduction in operating expenses, leading to a smaller loss from operations and an improved adjusted EBITDA loss. The company is awaiting FDA approval of Motiva Implants.

Establishment Labs reported a decrease in revenue for the first quarter of 2024 compared to the same period in 2023, but saw an increase in gross profit margin. The company reduced operating expenses and is making progress with FDA approval for Motiva Implants. Revenue guidance for 2024 remains between $174 million and $184 million.

Establishment Labs' fourth quarter revenue was $31.6 million, consistent with preannouncement. The company is focused on expense reduction, balance sheet security, and achieving positive adjusted EBITDA later this year and becoming cash flow positive in 2025.

Establishment Labs reported a slight increase in third-quarter revenue, up 0.8% year-over-year to $38.5 million. The company updated its 2023 revenue guidance to approximately $165 million, representing a 2% increase over 2022. However, the loss from operations widened to $21.0 million, and the net loss increased to $29.3 million.

Establishment Labs reported a record second quarter with a revenue of $48.6 million, an 18% increase year-over-year. The company is progressing with its U.S. PMA approval and commercialization preparations, alongside the global roll-out of Mia Femtech. A new Sulàyöm Innovation Campus was opened to expand manufacturing capacity and R&D capabilities.

Establishment Labs reported a record first quarter with worldwide revenue of $46.5 million, a 21.0% increase year-over-year. The company launched Mia Femtech™ in Japan and presented encouraging 3-year results from the Motiva® U.S. IDE study. A follow-on share offering was completed, raising gross proceeds of $90.4 million to support future growth initiatives.

Establishment Labs reported a record fourth quarter with worldwide sales of $43.8 million, a 24.1% increase year-over-year. The company submitted the fourth and final module to the U.S. FDA for premarket approval of Motiva Implants and provided 2023 revenue guidance of $200 million to $210 million.

Establishment Labs reported a strong third quarter in 2022, with worldwide sales reaching $38.2 million, a 31.7% increase year-over-year. The company has tightened its 2022 revenue guidance to a range of $158 million to $162 million, representing a 25% to 28% increase over 2021.

Establishment Labs reported a strong second quarter with worldwide sales of $41.2 million, a 28.7% increase year-over-year. Gross profit was 66.7% of revenue. The company is maintaining its 2022 revenue guidance of $155 million to $165 million.

Establishment Labs reported a strong first quarter with worldwide sales reaching $38.5 million, a 26.8% increase year-over-year. The company is maintaining its 2022 revenue guidance of $155 million to $165 million.

Establishment Labs reported a strong fourth quarter with record revenue of $35.3 million, a 31.0% increase year-over-year. Gross profit margin improved to 68.6%. The company provided 2022 revenue guidance of $155 million to $165 million, representing growth of 22% to 30%.

Establishment Labs reported a 27.6% increase in worldwide sales for the third quarter, reaching $29.0 million. The company has raised its full year 2021 revenue guidance to a range of $124 million to $128 million.

Establishment Labs reported a record second quarter revenue of $32.0 million, a 205% increase year-over-year. The company raised its full year 2021 revenue guidance to a new range of $122 million to $126 million.

Establishment Labs reported a record first quarter with worldwide sales of $30.3 million, a 24% increase year-over-year. The company raised its full-year 2021 revenue guidance to a range of $118 million to $122 million.

Establishment Labs reported a record fourth quarter revenue of $27.0 million, an 11% increase year-over-year. The company issued full year 2021 revenue guidance of $110 million to $112 million.

Establishment Labs reported third-quarter revenue of $22.8 million, comparable to the same period in 2019. The company reduced operating expenses by 23% and maintained a strong cash balance of $81.4 million. Full-year revenue guidance is projected to be $80 to $82 million.

Establishment Labs reported a challenging quarter impacted by COVID-19, but saw improvement throughout the quarter as countries reopened. Total revenues were $10.5 million, and the company reduced operating expenses by 27% compared to Q1 2020. The company's cash balance at June 30, 2020 was $86.4 million.

Establishment Labs reported a record first quarter with worldwide sales of $24.5 million, an 18% increase year-over-year. The company has taken measures to reduce expenses by approximately 20% in response to the COVID-19 impact and maintains a strong cash balance of $93.6 million.

Establishment Labs reported a 47.9% increase in fourth-quarter revenue compared to the previous year, reaching $24.2 million. The company's gross profit also rose to $16.4 million, with a reduced net loss of $5.5 million. They are closely monitoring the impact of Covid-19.